Novartis AG (NOVN) Given a CHF 88 Price Target by Morgan Stanley Analysts
A number of other brokerages have also recently issued reports on NOVN. Deutsche Bank AG set a CHF 83.50 price objective on Novartis AG and gave the stock a neutral rating in a research note on Wednesday, November 8th. set a CHF 90 price objective on Novartis AG and gave the stock a buy rating in a research note on Thursday, September 7th. UBS AG set a CHF 78 price objective on Novartis AG and gave the stock a neutral rating in a research note on Monday, August 28th. Kepler Capital Markets set a CHF 87 target price on Novartis AG and gave the stock a buy rating in a report on Monday, August 28th. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 target price on Novartis AG and gave the stock a neutral rating in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of CHF 86.10.
Novartis AG (VTX:NOVN) traded down CHF 0.20 on Tuesday, reaching CHF 81.90. The company had a trading volume of 1,570,000 shares, compared to its average volume of 4,020,000. Novartis AG has a 12 month low of CHF 67.80 and a 12 month high of CHF 85.40.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.